Navigation Links
Boston Biomedical Research Institute Maintains Baa3 Rating from Moody's
Date:3/25/2008

WATERTOWN, Mass., March 25 /PRNewswire/ -- Boston Biomedical Research Institute (BBRI) in Watertown, Massachusetts, was once again given a Baa3 bond rating with a stable outlook by Moody's Investor Services, affirming the Institute's financial stability in an era of declining NIH funding within an overall precarious economy that have left some similar organizations struggling to survive. "We are pleased with this confirmation of our financial health," says BBRI Director and Senior Staff Scientist Charlie Emerson, who adds that the Institute's research efforts continue to be robust and growing.

Boston Biomedical Research Institute is an independent, non-profit research institution devoted to increasing understanding of the causes, prevention and treatment of such diseases as heart disease, cancer, muscular dystrophy and Alzheimer's. Researchers at BBRI look at theses diseases at the biochemical and cellular level to unravel the mysteries of these diseases at their most rudimentary.

Moody's Investor Services, which is one of the two foremost credit rating organizations in the US, reported that: "The stable outlook reflects our expectation that BBRI's management is focused on containment of operating expenses and generation of new revenue streams in light of slowed federal research funding. We believe that the Institute's largely unrestricted financial resource base provides a good cushion for near-term operating pressure." The report added that " ... debt service reserve fund, security interest in gross receipts, and the first mortgage on the research facility provide some additional bondholder security."

According to Dr. Emerson, "Our commitment to diversify our streams of revenue is reflected in the hiring of a new director of advancement and in our decision to enhance board support, increase submissions to private foundations, increase planned giving, and pursue potential state funding, as possible supplemental funding resources."

'/>"/>
SOURCE Boston Biomedical Research Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
4. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. Boston Scientific Announces Election of Ray Elliott to Its Board of Directors
7. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
8. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
9. Genzyme Begins Major Expansion of Boston Manufacturing Facility
10. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
11. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... , July 24, 2015 Equity ... PDL BioPharma Inc. (NASDAQ: PDLI ), Arena Pharmaceuticals ... STEM ), Northwest Biotherapeutics Inc. (NASDAQ: NWBO ), ... research report on PDL BioPharma can be accessed at ... NASDAQ Composite ended at 5,146.41, down 0.49%, the Dow ...
(Date:7/24/2015)... -- The global next generation sequencing ... by 2022, growing at an estimated CAGR of 40.1% ... by Grand View Research, Inc. Development of faster, more ... significant reduction in cost of sequencing one base pair. ... of next generation sequencing throughout the forecast period. Revenue ...
(Date:7/23/2015)... Chicago, IL (PRWEB) , ... July 23, 2015 , ... ... family member, is pivotal in the management of a brain tumor diagnosis. The American ... family members at the ABTA’s 2015 Patient and Family Conference, July 24-25 in Chicago. ...
(Date:7/23/2015)... ... 2015 , ... July 23, 2015, Chicago - Advances in ... with fewer side effects, according to Erik P. Sulman, MD, PhD, associate professor ... American Brain Tumor Association (ABTA) National Patient and Family Conference in Chicago, July ...
Breaking Biology Technology:Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 5Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 2Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 3Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 4Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 5Reframing the Caregiver and Patient Mindset: Coping with the ‘New Normal’ 2Reframing the Caregiver and Patient Mindset: Coping with the ‘New Normal’ 3Radiation Oncology Advances Improve Safety and Efficacy of Treatment for Brain Tumors 2Radiation Oncology Advances Improve Safety and Efficacy of Treatment for Brain Tumors 3
... LLC announced today that the first patient has ... support a new fixed-dose combination (FDC) therapy for ... known as 572-Trii, will combine the investigational integrase ... reverse transcriptase inhibitor (NRTI) Kivexa®/Epzicom® (ABC/3TC). ...
... could jumpstart the promising field of cell therapy, in which ... of diseases and tissue defects, researchers at Brigham and Women,s ... the key challenges associated with the procedure: control of the ... reported in the journal Biomaterials on January 26, ...
... has become a standard tool in the search for ... disaster, but until now there has been very little ... policy challenges associated with this new use of genetic ... National Institutes of Health (NIH) has awarded Carnegie ...
Cached Biology Technology:Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 2Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 3Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 4Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 5Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 6Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 7Engineered cells could usher in programmable cell therapies 2Engineered cells could usher in programmable cell therapies 3CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices 2CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices 3CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices 4
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
(Date:7/27/2015)... 2015   Zynx Health ™, the market ... solutions, today announced that its ZynxCarebook ™ ... Android smartphones and tablets. With this expansion, care ... use ZynxCarebook to securely exchange messages and share ... transitions to other care settings, and improve clinical ...
(Date:7/23/2015)... Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... today reported financial results for its second quarter ended June ... of 2015 was $4.5 million, a decrease of 33% compared ... income in the second quarter of 2015 was $0.3 million, ... or $0.04 per diluted share, in the same period a ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... mice responsible for repairing DNA strands damaged by oxidation ... that such stress contributes to the development of cancer. ... DNA Repair by researchers at the National Institute ... University (OHSU) and the New York University School of ...
... measure organic contaminants in human body fluids, the National ... four new Standard Reference Materials (SRMs) available for purchase. ... and Prevention (CDC), the human milk and serum SRMs ... pesticides, commonly found in the U.S. population. Scientists at ...
... Netherlands: For the first time, researchers have been able ... of IVF treatment in blood. Dr. Cathy Allen, from the ... the European Society of Human Reproduction and Embryology today (Wednesday ... works for some patients but not for others. Previous ...
Cached Biology News:Genetically engineered mice yield clues to 'knocking out' cancer 2NIST issues human milk and blood serum SRMs for contaminant measurements 2Will IVF work for a particular patient? The answer may be found in her blood 2Will IVF work for a particular patient? The answer may be found in her blood 3